Newsroom

Sorted by: Latest
-

Zoetis Announces Proposed $1.75 Billion Convertible Senior Notes Offering

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE: ZTS) (the “Company” or “Zoetis”) today announced that, subject to market conditions, it intends to offer $1.75 billion aggregate principal amount of convertible senior notes due 2029 (the “Notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A of the Securities Act of 1933, as amended (the “Securities Act”). Zoetis also intends to grant the initial purchasers of the Notes an op...
-

NeoGenomics Announces that Natera Has Voluntarily Withdrawn its Appeal in Ongoing RaDaR Patent Litigation

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced that Natera has voluntarily withdrawn its appeal in ongoing RaDaR patent litigation....
-

Riassunto: SK Capital annuncia la sigla di un accordo definitivo per investire in Swixx BioPharma AG e dare impulso alla prossima fase di crescita ed espansione globale

NEW YORK--(BUSINESS WIRE)--SK Capital Partners, LP (“SK Capital”), un’impresa di investimento privata con sede a New York il cui focus è sui settori delle scienze della vita, dei materiali speciali e dei principi farmaceutici, oggi ha annunciato che una sua affiliata ha concluso un accordo per investire in Swixx BioPharma AG (“Swixx” o la “Società”) al fine di accelerare la prossima fase di crescita ed espansione globale della Società. L’investimento valuta la Società a oltre 1,5 miliardi di eu...
-

Samenvatting: SK Capital kondigt definitieve overeenkomst aan om te investeren in Swixx BioPharma AG om de volgende fase van groei en wereldwijde expansie te stimuleren

NEW YORK--(BUSINESS WIRE)--SK Capital Partners, LP (“SK Capital”), een in New York gevestigde particuliere investeringsmaatschappij die zich richt op de sectoren biowetenschappen, speciale materialen en ingrediënten, heeft vandaag bekendgemaakt dat haar dochteronderneming een overeenkomst heeft gesloten om te investeren in Swixx BioPharma AG (‘Swixx’ of het “Bedrijf”). De investering is erop gericht om de volgende fase van groei en wereldwijde expansie van het Bedrijf te versnellen. De invester...
-

SK Capital gibt endgültige Vereinbarung zur Investition in die Swixx BioPharma AG bekannt, um die nächste Phase des Wachstums und der globalen Expansion voranzutreiben

NEW YORK--(BUSINESS WIRE)--SK Capital Partners, LP („SK Capital“), eine in New York ansässige private Investmentgesellschaft mit Schwerpunkt auf den Bereichen Biowissenschaften, Spezialmaterialien und Inhaltsstoffe, gab heute bekannt, dass ihre Tochtergesellschaft eine Vereinbarung über eine Investition in die Swixx BioPharma AG („Swixx“ oder das „Unternehmen“) getroffen hat, um die nächste Wachstumsphase und die globale Expansion des Unternehmens zu beschleunigen. Die Investition bewertet das...
-

Resumen: SK Capital anuncia un acuerdo definitivo para invertir en Swixx BioPharma AG para impulsar la siguiente fase de crecimiento y expansión global

NUEVA YORK--(BUSINESS WIRE)--SK Capital Partners, LP (“SK Capital”), una firma de inversión privada con sede en Nueva York dedicada a los sectores de ciencias biológicas, materiales especializados e ingredientes, anunció hoy que su filial ha llegado a un acuerdo para invertir en Swixx BioPharma AG (“Swixx” o la “Empresa”) para acelerar la siguiente fase de crecimiento y expansión global de la Empresa. La inversión asigna un valor a la Empresa que supera 1500 millones de euros. Swixx es el líder...
-

SK Capital annonce une entente définitive en vue d’investir dans Swixx BioPharma AG afin de stimuler sa prochaine phase de croissance et d’expansion mondiale

NEW YORK--(BUSINESS WIRE)--SK Capital Partners, LP (« SK Capital »), société d'investissement privée basée à New York et spécialisée dans les domaines des sciences de la vie, des matériaux de spécialité et des ingrédients, a annoncé aujourd'hui que sa filiale avait conclu une entente en vue d'investir dans Swixx BioPharma AG (« Swixx » ou la « Société ») afin d'accélérer sa prochaine phase de croissance et d'expansion mondiale. Cet investissement valorise la Société à plus de 1,5 milliard d'eur...
-

Cencora Accelerates OneOncology Acquisition, Extending Solutions Offering for Community Oncology

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced it has entered into a definitive agreement to acquire the majority of the outstanding equity interests that it does not currently own in OneOncology, a physician-led national platform empowering independent medical specialty practices rooted in oncology, from TPG, a leading global alternative asset management firm. “We are excited to accelerate our acquisition of OneOncology, which will advance our management services...
-

Pebblebrook Hotel Trust Declares Dividends for Fourth Quarter 2025

BETHESDA, Md.--(BUSINESS WIRE)--Pebblebrook Hotel Trust Declares Dividends for Fourth Quarter 2025...
-

Companion Spine Announces FDA Premarket Approval (“PMA”) of the DIAM™ Spinal Stabilization System for the Treatment of Degenerative Disc Disease (“DDD”)

MÉRIGNAC, France--(BUSINESS WIRE)--Companion Spine, the French-American specialist in surgeon innovated spine implant surgery, announced that the U.S. Food and Drug Administration (the “FDA”) has approved the DIAM™ Spinal Stabilization System (P240043). DIAM™ Spinal Stabilization System is the first posterior motion-preserving device approved in the U.S. for the treatment of moderate to severe primary low back pain secondary to DDD at a single lumbar level (L2–L5) in patients who remain symptom...